Cargando…
Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account
INTRODUCTION: Survival modeling is a very important tool to detect risk factors and provide a basis for health care planning. However, cancer data may have properties leading to distorted results with routine methods. Therefore, this study aimed to cover specific factors (competing risk, cure fracti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747410/ https://www.ncbi.nlm.nih.gov/pubmed/29072428 http://dx.doi.org/10.22034/APJCP.2017.18.10.2825 |
_version_ | 1783289269116207104 |
---|---|
author | Ghavami, Vahid Mahmoudi, Mahmood Foroushani, Abbas Rahimi Baghishani, Hossein Shandiz, Fatemeh Homaei Yaseri, Mehdi |
author_facet | Ghavami, Vahid Mahmoudi, Mahmood Foroushani, Abbas Rahimi Baghishani, Hossein Shandiz, Fatemeh Homaei Yaseri, Mehdi |
author_sort | Ghavami, Vahid |
collection | PubMed |
description | INTRODUCTION: Survival modeling is a very important tool to detect risk factors and provide a basis for health care planning. However, cancer data may have properties leading to distorted results with routine methods. Therefore, this study aimed to cover specific factors (competing risk, cure fraction and heterogeneity) with a real dataset of Iranian breast cancer patients using a competing risk-cure-frailty model. MATERIALS AND METHODS: For this historical cohort study, information for 550 Iranian breast cancer patients who underwent surgery for tumor removal from 2001 to 2007 and were followed up to March 2017, was analyzed using R 3.2 software. RESULTS: In contrast to T-stage and N-stage, hormone receptor status did not have any significant effect on the cure fraction (long-term disease-free survival). However, T-stage, N-stage and hormone receptor status all had a significant effect on short-term disease-free survival so that the hazard of loco-regional relapse or distant metastasis in cases positive for a hormone receptor was only 0.3 times that for their negative hormone receptor counterparts. The likelihood of locoregional relapse in the first quartile of follow up was nearly twice that of other quartiles. The least cumulative incidence of time to locoregional relapse was for cases with a positive hormone receptor, low N stage and low T stage. The effect of frailty term was significant in this study and a model with frailty appeared more appropriate than a model without, based on the Akaike information criterion (AIC); values for the frailty model and one without the frailty parameter were 1370.39 and 1381.46, respectively. CONCLUSIONS: The data from this study indicate ae necessity to consider competing risk, cure fraction and heterogeneity in survival modeling. The competing risk-cure-frailty model can cover complex situations with survival data. |
format | Online Article Text |
id | pubmed-5747410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-57474102018-02-21 Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account Ghavami, Vahid Mahmoudi, Mahmood Foroushani, Abbas Rahimi Baghishani, Hossein Shandiz, Fatemeh Homaei Yaseri, Mehdi Asian Pac J Cancer Prev Research Article INTRODUCTION: Survival modeling is a very important tool to detect risk factors and provide a basis for health care planning. However, cancer data may have properties leading to distorted results with routine methods. Therefore, this study aimed to cover specific factors (competing risk, cure fraction and heterogeneity) with a real dataset of Iranian breast cancer patients using a competing risk-cure-frailty model. MATERIALS AND METHODS: For this historical cohort study, information for 550 Iranian breast cancer patients who underwent surgery for tumor removal from 2001 to 2007 and were followed up to March 2017, was analyzed using R 3.2 software. RESULTS: In contrast to T-stage and N-stage, hormone receptor status did not have any significant effect on the cure fraction (long-term disease-free survival). However, T-stage, N-stage and hormone receptor status all had a significant effect on short-term disease-free survival so that the hazard of loco-regional relapse or distant metastasis in cases positive for a hormone receptor was only 0.3 times that for their negative hormone receptor counterparts. The likelihood of locoregional relapse in the first quartile of follow up was nearly twice that of other quartiles. The least cumulative incidence of time to locoregional relapse was for cases with a positive hormone receptor, low N stage and low T stage. The effect of frailty term was significant in this study and a model with frailty appeared more appropriate than a model without, based on the Akaike information criterion (AIC); values for the frailty model and one without the frailty parameter were 1370.39 and 1381.46, respectively. CONCLUSIONS: The data from this study indicate ae necessity to consider competing risk, cure fraction and heterogeneity in survival modeling. The competing risk-cure-frailty model can cover complex situations with survival data. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5747410/ /pubmed/29072428 http://dx.doi.org/10.22034/APJCP.2017.18.10.2825 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Research Article Ghavami, Vahid Mahmoudi, Mahmood Foroushani, Abbas Rahimi Baghishani, Hossein Shandiz, Fatemeh Homaei Yaseri, Mehdi Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title_full | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title_fullStr | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title_full_unstemmed | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title_short | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account |
title_sort | long-term disease-free survival of non-metastatic breast cancer patients in iran: a survival model with competing risks taking cure fraction and frailty into account |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747410/ https://www.ncbi.nlm.nih.gov/pubmed/29072428 http://dx.doi.org/10.22034/APJCP.2017.18.10.2825 |
work_keys_str_mv | AT ghavamivahid longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount AT mahmoudimahmood longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount AT foroushaniabbasrahimi longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount AT baghishanihossein longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount AT shandizfatemehhomaei longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount AT yaserimehdi longtermdiseasefreesurvivalofnonmetastaticbreastcancerpatientsiniranasurvivalmodelwithcompetingriskstakingcurefractionandfrailtyintoaccount |